

Hydroxycarbamide (hydroxyurea)



Essential medicine status

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

		EMLc	ATC codes: L01XX05
Indication	Chronic myeloid leukaemia, not elsewhere classified	ICD11 code: 2C03.2	
INN	Hydroxycarbamide		
Medicine type	Chemical agent		
List type	Complementary (EML) (EMLc)		
Formulations	Oral > Solid > dosage form: 200 mg ; 300 mg ; 400 mg ; 500 mg ; 1 g ; 100 mg (EMLc)		
EML status history	First added in 2009 (TRS 958) Changed in 2015 (TRS 994) Changed in 2019 (TRS 1021) Changed in 2023 (TRS 1049)		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more about patents .		
Tags	Cancer		
Wikipedia	Hydroxycarbamide (hydroxyurea)		
DrugBank	Hydroxycarbamide (Hydroxyurea)		

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the deletion of hydroxycarbamide 250 mg solid oral dosage from the EML and EMLc, and the addition of hydroxycarbamide 100 mg solid oral dosage form to the EMLc.

